**Supplementary Material.** Demographic and genetics characteristics of the cohort.

| Patient ID | Age* | Sex | Indication | Sanger Sequencing (DNA_000585.5/hCAM) classification | | MLPA | Final Molecular Diagnosis |
|---|---|---|---|---|---|---|---|
| P1 | 17 | F | Puberty Problems | c.518T>A p.(Ile173Asn)/ P(PSFL/PS1/PM1/PM2/PP2/PP3) | c.1447C>T p.(Pro483Ser)/P(PSFL/PM2/PP2/PP5) | No Reportable Variant | Compound Heterozygous |
| P2 | 16 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P3 | 12 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P4 | 17 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P5 | 18 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P6 | 17 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P7 | 16 | F | Puberty Problems | c.844G>T p.(Val282Leu)/ (PSFL/PM1/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P8 | 5 | F | Disorder of Sexual Development | c.702T>G p.(Ile151Met)/ P(PSFL/PS1/PM1/PM2/PP2/PM1) | | No Reportable Variant | Heterozygous |
| P9 | 9 | F | Family History | Exon 6-8 micro conversion | | Exon 6-8 micro conversion | Heterozygous |
| P10 | 0 | F | Adrenal Insufficiency | No Reportable Variant | | No Reportable Variant | - |
| P11 | 15 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P12 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P13 | 7 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P14 | 5 | F | Clinical Diagnosis | c.293-13A/C>G /P(PM2/PM3/PS3) | | No Reportable Variant | Homozygous |
| P15 | 8 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P16 | 15 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P17 | 12 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P18 | 10 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | Exon 1-3 deletion | Compound Heterozygous |
| P19 | 0 | M | Disorder of Sexual Development | c.518T>A p.(Ile173Asn)/P(PSFL/PS1/PM1/PM2/PP2/PP3) | | No Reportable Variant | Homozygous |
| P20 | 11 | F | Puberty Problems | c.293-13A/C>G /P(PM2/PM3/PS3) | Exon 4-8 micro conversion | Exon 4-8 micro conversion | Homozygous |
| P21 | 10 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P22 | 7 | M | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P23 | 13 | F | Clinical Diagnosis | c.961G>A p.(Glu321Lys)/(PSFL/PM2/PP2/PP3) | c.293-13A/C>G /P(PM2/PM3/PS3) | No Reportable Variant | Compound Heterozygous |
| P24 | 10 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | c.1360C>T p.(Pro454Ser)/ P(PSFL/PM2/PP2/PP5) | No Reportable Variant | Compound Heterozygous |
| P25 | 17 | F | Puberty Problems | c.844G>T p.(Val282Leu) / (PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P26 | 17 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P27 | 9 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P28 | 7 | F | Clinical Diagnosis | c.293-13A/C>G /P(PM2/PM3/PS3) | | No Reportable Variant | Homozygous |
| P29 | 0 | F | Clinical Diagnosis | c. 1901C>T, c.1906C>T/ p. (Gln313*,Arg636Trp)/ P(PSFL/PS1/PM1/PM2/PP2/PP3) (heterozygous) | Exon 4-8 micro conversion | Exon 4-8 micro conversion | Compound Heterozygous |
| P30 | 7 | M | Clinical Diagnosis | c.1105C>A/ c.1360C>T/ p.(Pro454Ser;Arg340His) /(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P31 | 0 | F | Disorder of Sexual Development | No PCR products | | CAH Xchromosyngeo large deletion) | Homozygous |
| P32 | 0 | F | Disorder of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P33 | 0 | F | Disorder of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P34 | 0 | M | Disorder of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P35 | 0 | M | Disorder of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P36 | 11 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | c.1447C>T p.(Pro483Ser)/ (PSFL/PM2/PP2/PP5) | No Reportable Variant | Compound Heterozygous |
| P37 | 16 | F | Clinical Diagnosis | c.293-13A/C>G /P(PM2/PM3/PS3) | | Exon 1-3 deletion | Compound Heterozygous |
| P38 | 10 | M | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P39 | 12 | F | Puberty Problems | c.392G>A p.(Gly131Asp)/VUS(PM2/PP2) | | No Reportable Variant | Homozygous |
| P40 | 0 | M | Clinical Diagnosis | c.293-13A/C>G /P(PM2/PM3/PS3) | Exon 4-9 micro conversion | Exon 4-9 micro conversion | Compound Heterozygous |
| P41 | 0 | M | Disorder of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P42 | 14 | F | Clinical Diagnosis | c.293-13A/C>G /P(PM2/PM3/PS3) | | No Reportable Variant | Homozygous |
| P43 | 0 | M | Disorder of Sexual Development | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P44 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P45 | 15 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P46 | 3 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P47 | 8 | F | Clinical Diagnosis | No Reportable Variant | | No Reportable Variant | - |
| P48 | 15 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P49 | 0 | F | Clinical Diagnosis | c.702T>G p.(Ile151Leu)/(PSFL/PS1/PM1/PM2/PP2/PM1) | | No Reportable Variant | Homozygous |
| P50 | 13 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P51 | 0 | F | Abnormal Screening Test | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P52 | 0 | M | Abnormal Screening Test | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P53 | 10 | M | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P54 | 9 | M | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P55 | 0 | M | Disorder of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P56 | 15 | M | Puberty Problems | c.1447C>T p.(Pro483Ser)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P57 | 5 | F | Clinical Diagnosis | c.1360C>T p.(Pro454Ser)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P58 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P59 | 8 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | Exon 1-3 deletion | Compound Heterozygous |
| P60 | 10 | M | Puberty Problems | c.518T>A p.(Ile173Asn)/P(PM1/PS1/PM1/PM2/PP2/PP3) | c.1505C>T p.(Arg503Trp)/ P(PSFL/PS1/PM5/PM1/PM2/PP3) | No Reportable Variant | Compound Heterozygous |
| P61 | 9 | M | Adrenal Insufficiency | No Reportable Variant | | No Reportable Variant | - |
| P62 | 6 | F | Adrenal Insufficiency | No Reportable Variant | | No Reportable Variant | - |
| P63 | 0 | F | Clinical Diagnosis | c.950C>T p.(Ser317Phe)/PVS1,PM3,PS3) | | No Reportable Variant | Homozygous |
| P64 | 13 | M | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | c.293-13A/C>G /P(PM2/PM3/PS3) | No Reportable Variant | Compound Heterozygous |
| P65 | 15 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P66 | 0 | F | Clinical Diagnosis | Exon 4-9 micro conversion | | Exon 4-9 micro conversion | Homozygous |
| P67 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P68 | 1 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P69 | 9 | M | Puberty Problems | c.1447C>T p.(Pro483Ser)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P70 | 0 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | c.269C>T p.(Ala90Val)/ VUS(PM2/PP2) | No Reportable Variant | Compound Heterozygous |
| P71 | 7 | M | Puberty Problems | c.844G>T p.(Val282Leu) / (PSFL/PM2/PP2/PP5) | | Total gene deletion | Compound Heterozygous |
| P72 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P73 | 10 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P74 | 0 | F | Clinical Diagnosis | c.844G>T p.(Val282Leu) /(PSFL/PM2/PP2/PP5) | c.293-13A/C>G /P(PM2/PM3/PS3) | No Reportable Variant | Compound Heterozygous |
| P75 | 0 | F | Disorder of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P76 | 11 | F | Family History | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | c.955C>T p.(Gln319*)/ P(PVS1,PM3,PS3) | No Reportable Variant | Compound Heterozygous |
| P77 | 15 | M | Puberty Problems | c.1360C>T p.(His454Tyr) | | No Reportable Variant | Heterozygous |
| P78 | 11 | F | Family History | c.392G>A p.(Gly131Asp)/ VUS(PM2/PP2) | c.844G>T p.(Val282Leu) / (PSFL/PM2/PP2/PP5) | No Reportable Variant | Compound Heterozygous |
| P79 | 14 | M | Family History | c.392G>A p.(Gly131Asp)/VUS(PM2/PP2) | | No Reportable Variant | Homozygous |
| P80 | 12 | F | Family History, Disorder of Sexual Development | c.392G>A p.(Gly131Asp)/VUS(PM2/PP2) | | No Reportable Variant | Homozygous |
| P81 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P82 | 5 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P83 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P84 | 12 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P85 | 10 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P86 | 12 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P87 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P88 | 16 | F | Puberty Problems | c.844G>T p.(Val282Leu) / (PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P89 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P90 | 0 | F | Disorder of Sexual Development | c.850A>G p.(Met284Val)/ P(PM1,PM3,PM2,PP2) | | No Reportable Variant | Heterozygous |
| P91 | 4 | M | Family History | c.293-13A/C>G /P(PM2/PM3/PS3) | c.397C>T p.(Arg133Cys) /(PSFL/PM1/PM2/PP2) | No Reportable Variant | Compound Heterozygous |
| P92 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P93 | 9 | F | Puberty Problems | c.844G>T p.(Val282Leu) / (PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P94 | 15 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P95 | 12 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P96 | 11 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | Exon 4 micro conversion | Exon 4 micro conversion | Compound Heterozygous |
| P97 | 15 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P98 | 0 | F | Disorder of Sexual Development | c.844G>T p.(Val282Leu) / (PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P99 | 11 | M | Clinical Diagnosis | c.702T>G p.(Ile151Leu)/(PSFL/PS1/PM1/PM2/PP2/PM1) | c.844G>T p.(Val282Leu) / (PSFL/PM2/PP2/PP5) | No Reportable Variant | Compound Heterozygous |
| P100 | 0 | F | Puberty Problems | c.861C>T p.(Leu289Phe)/ VUS(PM1/PM2/PP2) | | No Reportable Variant | Heterozygous |
| P101 | 0 | M | Abnormal Screening Test | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P102 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P103 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P104 | 16 | M | Clinical Diagnosis | c.1360C>T p.(Arg357Trp) /P(PM1/PS3/PM5/PP1/PP2/PP3) | c.1360C>T p.(Pro454Ser) / P(PSFL/PM2/PP2/PP5) | No Reportable Variant | Compound Heterozygous |
| P105 | 7 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P106 | 12 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P107 | 9 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P108 | 8 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | c.1352C>T p.(Thr451Met)/ VUS(PM1,PM2,PP2) | No Reportable Variant | Compound Heterozygous |
| P109 | 1 | F | Clinical Diagnosis | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | c.1505C>T p.(Arg503Trp) /P(PM5,PS3,PM5,PP1, PM2,PP3) | No Reportable Variant | Compound Heterozygous |
| P110 | 6 | M | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P111 | 3 | M | Puberty Problems | Exon 4 micro conversion | | Exon 4 micro conversion | Homozygous |
| P112 | 15 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P113 | 16 | F | Puberty Problems | c.392G>A p.(Gly131Asp)/VUS(PM2/PP2) | | No Reportable Variant | - |
| P114 | 11 | F | Clinical Diagnosis | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P115 | 6 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P116 | 9 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P117 | 8 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P118 | 15 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P119 | 13 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P120 | 7 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P121 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P122 | 3 | M | Clinical Diagnosis | c.86A>C p.(Hs29Pro) | Exon 1 deletion | Exon 1 deletion | Compound Heterozygous |
| P123 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P124 | 9 | M | Adrenal Insufficiency | No Reportable Variant | | No Reportable Variant | - |
| P125 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P126 | 9 | M | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P127 | 8 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P128 | 15 | F | Puberty Problems | c. 1174G>A p.(Ala392Thr) | | No Reportable Variant | Heterozygous |
| P129 | 0 | F | Puberty Problems | c.293-13A/C>G /P(PM2/PM3/PS3) | | No Reportable Variant | Heterozygous |
| P130 | 10 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P131 | 6 | F | Puberty Problems | c.1384A>T p.(Hs462Leu) | | No Reportable Variant | Heterozygous |
| P132 | 15 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P133 | 7 | F | Puberty Problems | c.1360C>T p.(Pro454Ser)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P134 | 8 | F | Clinical Diagnosis | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P135 | 9 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P136 | 15 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P137 | 5 | F | Incidental ACTH Elevation | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P138 | 10 | F | Clinical Diagnosis | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P139 | 14 | F | Clinical Diagnosis | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P140 | 15 | F | Clinical Diagnosis | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | c.293-13A/C>G /P(PM2/PM3/PS3) | No Reportable Variant | Compound Heterozygous |
| P141 | 17 | F | Puberty Problems | c.1360C>T p.(Pro454Ser)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P142 | 15 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | c.293-13A/C>G /P(PM2/PM3/PS3) | No Reportable Variant | Compound Heterozygous |
| P143 | 7 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P144 | 11 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P145 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P146 | 8 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P147 | 16 | F | Puberty Problems | Exon 4 micro conversion | | Exon 4 micro conversion | Heterozygous |
| P148 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P149 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P150 | 18 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P151 | 18 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P152 | 7 | F | Clinical Diagnosis | c.961G>A p.(Glu321Lys)/(PSFL/PM2/PP2/PP3) | c.293-13A/C>G /P(PM2/PM3/PS3) | No Reportable Variant | Compound Heterozygous |
| P153 | 12 | F | Puberty Problems | c.1360C>T p.(Pro454Ser)/(PSFL/PM2/PP2/PP5) | c.1035G>A p.(Arg345Arg)/ (PSFL/PM2/PP2/PM3) | No Reportable Variant | Compound Heterozygous |
| P154 | 16 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P155 | 12 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P156 | 10 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P157 | 1 | M | Disorder of Sexual Development | Exon 4 micro conversion | | Exon 4 micro conversion | Homozygous |
| P158 | 6 | F | Puberty Problems | c.1360C>T p.(Pro454Ser)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P159 | 0 | M | Disorder Of Sexual Development | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | c.955C>T p.(Gln319*)/ P(PVS1,PM3,PS3) | No Reportable Variant | Compound Heterozygous |
| P160 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P161 | 3 | M | Clinical Diagnosis | c.293-13A/C>G /P(PM2/PM3/PS3) | | No Reportable Variant | Homozygous |
| P162 | 7 | M | Clinical Diagnosis | c.955 C>T p.(Gln319*)P(PVS1,PM3,PS3) | | No Reportable Variant | Homozygous |
| P163 | 7 | M | Disorder Of Sexual Development | c.1360C>T p.(Pro454Ser)/(PSFL/PM2/PP2/PP5) | | Exon 1 micro conversion | Heterozygous |
| P164 | 9 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P165 | 5 | F | Puberty Problems | Exon 4 micro conversion | | Exon 4 micro conversion | Homozygous |
| P166 | 13 | M | Puberty Problems | c.850A>G p.(Met284Val)/ P(PM1,PM3,PM2,PP2) | | Total gene deletion | Compound Heterozygous |
| P167 | 12 | M | Puberty Problems | Exon 4 micro conversion | | Exon 4 micro conversion | Homozygous |
| P168 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P169 | 11 | F | Puberty Problems | c.1360C>T p.(Pro454Ser)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P170 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P171 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P172 | 8 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P173 | 0 | M | Disorder Of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P174 | 15 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P175 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P176 | 11 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P177 | 11 | F | Disorder Of Sexual Development | c.955C>T p.(Gln319*)/ P(PVS1,PM3,PS3) | c.293-13A/C>G /P(PM2/PM3/PS3) | No Reportable Variant | Compound Heterozygous |
| P178 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P179 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P180 | 0 | F | Abnormal Screening Test | c.861C>T p.(Leu289Phe) /VUS(PM1,PM2,PP2) | | No Reportable Variant | Heterozygous |
| P181 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P182 | 8 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P183 | 14 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P184 | 0 | F | Clinical Diagnosis | c.518 T>A p.(Ile173Asn) /P(PM1/PS1/PM1/PM2/PP2/PP3) | c.955C>T p.(Gln319*)/ P(PVS1,PM3,PS3) | No Reportable Variant | Compound Heterozygous |
| P185 | 12 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P186 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P187 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P188 | 16 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P189 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P190 | 14 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P191 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P192 | 8 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P193 | 16 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P194 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P195 | 0 | M | Disorder Of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P196 | 15 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P197 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P198 | 14 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P199 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P200 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P201 | 0 | F | Disorder Of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P202 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P203 | 17 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P204 | 15 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P205 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P206 | 17 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P207 | 7 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P208 | 0 | F | Clinical Diagnosis | c.950C>T p.(Ser317Phe)/PVS1,PM3,PS3) | | No Reportable Variant | Homozygous |
| P209 | 0 | M | Disorder Of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P210 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P211 | 0 | M | Disorder Of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P212 | 0 | M | Abnormal Screening Test | c.1360C>T p.(Pro454Ser)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P213 | 16 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P214 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P215 | 8 | M | Puberty Problems | Exon 4 micro conversion | | Exon 4 micro conversion | Heterozygous |
| P216 | 9 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P217 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P218 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P219 | 0 | M | Abnormal Screening Test | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | - |
| P220 | 7 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P221 | 17 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P222 | 11 | F | Disorder Of Sexual Development | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P223 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P224 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P225 | 0 | F | Clinical Diagnosis | c.293-13A/C>G /P(PM2/PM3/PS3) | Exon 4 micro conversion | Exon 4 micro conversion | Compound Heterozygous |
| P226 | 9 | M | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P227 | 6 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P228 | 0 | F | Disorder Of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P229 | 15 | F | Puberty Problems | c.1360C>T p.(Arg357Trp)/(PSFL/PM1/PS3/PM5/PP1/PP2/PP3) | | No Reportable Variant | Heterozygous |
| P230 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P231 | 0 | F | Clinical Diagnosis | c.293-13A/C>G /P(PM2/PM3/PS3) | | No Reportable Variant | Heterozygous |
| P232 | 15 | M | Disorder Of Sexual Development | No Reportable Variant | | No Reportable Variant | - |
| P233 | 0 | M | Disorder Of Sexual Development | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Heterozygous |
| P234 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P235 | 17 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P236 | 5 | F | Puberty Problems | c.293-13A/C>G /P(PM2/PM3/PS3) | | No Reportable Variant | Heterozygous |
| P237 | 15 | F | Puberty Problems | c.293-13A/C>G /P(PM2/PM3/PS3) | | No Reportable Variant | - |
| P238 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P239 | 0 | M | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P240 | 0 | F | Clinical Diagnosis | Exon 1-3 micro conversion | Total gene conversion | Exon 1-3 micro conversion, Total gene conversion | Compound Heterozygous |
| P241 | 9 | M | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P242 | 8 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P243 | 7 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P244 | 8 | F | Puberty Problems | c.844G>T p.(Val282Leu)/(PSFL/PM2/PP2/PP5) | | No Reportable Variant | Homozygous |
| P245 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P246 | 0 | F | Abnormal Screening Test | No Reportable Variant | | No Reportable Variant | - |
| P247 | 7 | F | Clinical Diagnosis | c.293-13A/C>G /P(PM2/PM3/PS3) | | Exon 1-3 deletion | Compound Heterozygous |
| P248 | 13 | M | Adrenal Insufficiency | No Reportable Variant | | No Reportable Variant | - |
| P249 | 17 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P250 | 15 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P251 | 9 | F | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |
| P252 | 8 | M | Puberty Problems | No Reportable Variant | | No Reportable Variant | - |

* Designates ages of the probands when tested P:Pathogenic, LP: Likely pathogenic, VUS: Variant of unknown significance F: Female, M: Male.